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Abstract 
Background:  Perfluoroalkyl and polyfluoroalkyl substances (PFASs) are persistent synthetic 
compounds that may have associated health risks.   
Purpose: To explore the association between four common detectable serum PFASs 
perfluorooctanoic acid (PFOA), perfluorooctyl sulfonate (PFOS), perfluorohexane sulfonate 
(PFHxS), and perfluorononanoic acid (PFNA) and cancer risk in United States (U.S.) adults. 
Methods: Data from 4,497 participants from the 2011–2016 National Health and Nutrition 
Examination Survey (NHANES) were analyzed.  Gender stratified adjusted logistic regression 
analysis was conducted to determine association between serum PFASs tertiles and risk of 
cancer.  
Results:  Median (IQR) PFASs were significantly higher in men compared to women, and 
among individual with cancer than healthy participants (p < .05 for both).  In unadjusted analysis, 
a significantly high risk of cancer was noted in males in high PFOS tertile compared to low 
group the unadjusted odds of cancer in males were 115% (OR 2.15; 95% CI 1.502, 3.078; p 
< .001) elevated in high PFOS tertile compared to referent.  In unadjusted analysis, a 
significantly elevated risk of cancer was noted in females for PFOA, PFOS, PFHxS high tertile 
as well as medium tertile compared to low group.  The unadjusted odds of cancer in females 
were 132%, p < .001, 157%, p < .001, 235%; p < .001 elevated in women in high PFOA, PFOS, 
PFHxS tertile, respectively compared to low group. In adjusted models no significant association 
between PFAS serum levels and cancer was observed in men or women. 
Conclusion: In U.S. adults, serum PFASs levels were not significantly associated with cancer. 
Keywords:  perfluoroalkyl substances, NHANES, public health, cancer 
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The relationship of perfluoroalkyl and polyfluoroalkyl substances and cancer risk: 
2011 – 2016 NHANES Data 
Perfluoroalkyl and polyfluoroalkyl substances (PFAS) represents a family of manmade 
chemicals that contain a carbon and fluorine backbone.  They are part of a larger universe of 
organic and inorganic substances that contain at least 1 Fluorine atom, with vastly different 
physical, chemical, and biologic properties called ‘fluorinated substances’ (Buck et al., 2011). 
There are hundreds of PFAS compounds with a varying functional group or groups which can 
include other elements such as oxygen, hydrogen, or sulfur.  Originally fabricated in 1950, PFAS 
compounds have been used extensively in commercial and industrial applications: textiles, stain 
and soil repellents, and aqueous film-forming foams used frequently in fire-fighting (Buck et al., 
2011).   
Over the past half of a century, the ubiquitous use of these compounds and their 
subsequent discharge into the environment has led to the detection of these compounds at all 
ecological levels, including human beings (Hu et al., 2016).  However, despite the United States 
(U.S.) and global interventions on PFAS production, reduction, and elimination, these long-
lasting compounds are now ubiquitous in our environment which makes understanding their 
impact paramount (Mueller & Yingling, 2017). 
Research Question 
 What impact do PFAS's (perfluoroalkyl and polyfluoroalkyl substances) exposure have 
on the risk of cancer among the adult population (≥ 20 years) in the U.S.?  Since PFASs have 
been shown to increase risk of cancer in animal models and limited human studies (Barry, 
Winquist, & Steenland, 2013), we hypothesize that there will be an association between 
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detectable PFASs levels in serum and the presence of cancer in adults aged 20 years and greater 
within the U.S.  
Literature Review 
Human Exposure to PFAS 
During production and use, PFAS can migrate into the soil, water, and air.  Most PFAS 
(including PFOA and PFOS) do not breakdown, so they remain in the environment.  Because of 
their widespread use and their persistence in the environment, PFAS are found in the blood of 
people and animals all over the world and are present at low levels in a variety of food products 
and in the environment.  Some PFAS can build up in people and animals with repeated exposure 
over time (Mueller & Yingling, 2017). 
Health Effects of PFAS 
Many researchers have targeted the potential relationship of PFAS to multiple health 
effects.  These include, but are not limited to, PFAS affecting growth, learning, and behavior of 
infants and older children, lowering a woman’s chance of getting pregnant, interfering with the 
body’s natural hormones, increase cholesterol levels, affecting the immune system, and increase 
the risk of cancer (Lefebvre et al., 2008). 
PFAS and Cancer Risk 
Overall, there have been a limited number of studies focused on the potential relationship 
of PFAS to cancer risk.  Animal studies in rats have shown a statistically significant (p ≤ 0.05) 
increased incidence of Leydig cell tumors and adenomas of the testes, liver, and pancreas and 
hyperplasia when fed 300 ppm ammonium perfluorooctanoate (PFOA or also referred to as C8 in 
the literature) (Butenhoff, Kennedy, Chang, & Olsen, 2012).  Thomford (2002) demonstrated 
increased incidence (p ≤ 0.05) of hepatocellular adenomas in male rats fed high dose PFOS (20 
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ppm) for two years compared to controls.  In addition, female rats in the same study showed also 
demonstrated a dose related increase in hepatocellular adenomas but also had a non-dose related 
increase in mammary gland adenomas (0.5 ppm).  Other polyfluorinated compounds have also 
shown animal carcinogenicity such as 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy) propionic acid, 
ammonium salt (CAS 62037-80-3) which showed increases in liver adenomas in rats (Anand, 
2013).  The increase in liver associated lesions is not surprising given that the liver is the main 
target organ for PFAS compounds.  It is thought that one mechanism of action for this is the 
proliferation of peroxisomes and increased liver mitogenesis that was associated with PFOA 
(Biegel, Hurtt, Frame, O’Conner, & Cook, 2001). PFOA mechanism of action on the Leydig cell 
tumors was thought to be related to PFOA inhibiting testosterone biosynthesis and increases in 
serum estradiol levels via induction of hepatic aromatase activity (Liu, Hurtt, Cook, & Biegel, 
1996). And likewise, pancreatic acinar cell proliferation is also thought to be related to secondary 
PFOA liver effects. 
Human studies are limited in nature and the majority are occupational cohort studies. 
Human data for cancer from two occupational cohorts are limited to mortality and are based on small 
numbers.  One of the two cohorts showed increased kidney cancer (Leonard, Kreckmann, Sakr, 
& Symons, 2008), and the other showed positive exposure–response trends for pancreatic and 
prostate cancer that were not statistically significant (Lundin, Alexander, Olsen, & Church, 
2009).  In a prospective Danish cohort study, plasma concentrations of background PFOA 
exposures were not associated with prostate, bladder, pancreatic, or liver cancer (Eriksen et al., 
2009).  A case-control study of Greenland Inuit women found a positive but not statistically 
significant association between PFOA exposure and breast cancer (Bonefeld-Jorgensen et al., 
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2011).  The positive associations were generally not consistent among cancer sites between 
studies, and for the remaining cancer sites reported, no associations were observed. 
Methods 
Data Source and Study Sample 
Data for three survey cycles from 2011-2012, 2013-2014, and 2015-2016 were obtained 
from the freely available National Health and Nutrition Examination Survey (NHANES), which 
is a population-based survey.  NHANES collects individual, laboratory and physical examination 
information about noninstitutionalized U.S. individuals every two years.  The survey’s goal is to 
collect a representative sample of the U.S. population.  All survey operations manuals, brochures 
and consent documents for the dataset are publicly available on the NHANES website as part of 
the Centers for Disease Control and Prevention (CDC).  
NHANES is a program of studies designed to assess the health and nutritional status of 
adults and children in the United States.  The survey is unique in that it combines interviews and 
physical examinations.  This process is broken down to three steps: a doorstep screener with a 
brief interview for exclusion criteria, and in-depth confidential home interview, and a health 
examination performed in the Mobile Examination Center (MEC) that contains high-tech 
medical equipment and allows for in depth laboratory analysis.  From the 2011-2016 NHANES 
combined dataset, individuals with data available for the four PFASs in question were included 
in the studied population. 
PFAS Concentration Measured via Serum Analysis 
The CDC sponsored NHANES website provides in depth protocol for each of the 
laboratory measure collected in the MEC.  Online solid phase extraction coupled to high 
performance liquid chromatography-turboionspray ionization-tandem mass spectrometry (online 
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SPE-HPLC-TIS-MS/MS) is used for the quantitative detection of PFAS (Kuklenyik, Needham, 
& Calafat, 2005).  The lower limit of detection (LLOD) for each PFAS was 0.10 ng/mL.  If a 
sample had analytic results below the LLOD, an imputed value was placed in the database for 
that sample by the NHANES study designers.  Given the skewed distribution serum PFAS 
among participants included in the study, each of the four serum PFASs were split in into equal 
tertiles: low, medium, and high based on gender specific cutoff points. 
Confounders  
Socioeconomic and sociodemographic information (i.e., age, race/ethnicity, gender, and 
income) were collected by trained interviewers using the in-home NHANES Family 
Questionnaire via the Computer-Assisted Personal interview (CAPI) system.  Race/Ethnicity was 
reported as Hispanic, non-Hispanic White, non-Hispanic Black, and other multi-racial (referent 
category).  Race and income were recoded from the NHANES data set to form three categories: 
non-Hispanic White (NHW), non-Hispanic Black (NHB), and others.  Income was recoded into 
low ($0 to, 24,999/year), medium (25,000 to 54,999/year, and high categories ($55,000+/year).  
Statistical Analysis 
Data analyses were performed Statistical Package for the Social Science (SPSS) version 
26.0 (IBM Corp, Released 2019).  Descriptive statistics for continuous variables such as age and 
PFAS included measures of centrality (mean or median) and dispersion (standard deviation or 
interquartile range) overall and by gender, and by presence of cancer.  Frequency distributions 
were computed for categorical variables (race, income). 
Across gender statistical significance for continuous variables were tested using Student’s 
2-tailed t-test for normally distributed variables (age) and the Mann-Whitney U test for non-
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normal (non-parametric variables) (PFASs).  For categorical variables (race and income), 
difference were computed with the Chi-square test. 
To determine independent association between PFAS serum levels and cancer, logistic 
regression analysis was performed.  Exposure was categorized as gender specific PFAS tertiles 
(low, medium, and high).  The low category was used as the referent to compare with medium 
and high categories.  In the first logistic regression model (unadjusted) only cancer outcome and 
PFAS exposure as tertiles was entered (each PFAS was modeled separately) which compared the 
odd of cancer in individual who had medium or high serum PFAS exposure compared to the 
referent or low category.  The second model was adjusted for age and the third model was 
adjusted for age, income, and race.  The odds ratio (OR) and 95% confidence interval (CI) of risk 
of cancer per exposure level to the four PFASs were reported with the two tailed p-value used at 
an α = 0.05 significance level. 
Results 
Descriptive Statistics 
The descriptive statistics of the overall study population and by gender are included in 
Table 1.  The p-value represents comparison between gender.  The average age was 49.03 and 
did not differ significantly between genders.  Overall, the predominant income bracket was 
annual household income of $55,000.  Income distribution was statistically different between 
genders.  The ethnicity groups overall showed a predominance of the “other” category and were 
not significantly different among genders.  Each of the PFAS selected for this study were 
significantly higher among males; however, cancer rates between genders were not significantly 
different. 
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Table 1 
Descriptive Characteristics of NHANES 2011-2016 Participants, Overall and by Gender  
   Overall Male Females p-value*  
Age (years), mean ± SD  49.03±17.63  49.09±17.64  48.97±17.62  0.806  
Annual Household Income, n 
(%)  
      0.019  
     < $25, 000 1,347(30.0)  601(28.0)  746(31.8)    
     $25,000 to 54,999 1,368 (30.4)  664 (30.9)  704 (30.0)    
     > 55,000  1,782 (39.6)  883(41.1)  899 (38.3)    
Ethnicity, n (%)        0.772  
     NHW  1,723 (38.3)  836(38.9)  887(37.8)    
     NHB  1,020 (22.7)  481(22.4)  539(22.9)    
     Others  1,754(39.0)  851(38.7)  923(39.3)    
PFASs (ng/mL) median, IQR           
     PFOA  1.90 (1.26-2.80)  2.17(1.54-
3.07)  
1.57(0.970-2.49)  <0.001  
     PFOS  6.00 (3.40-10.2)  7.63(4.82-
12.2)  
4.59(2.50-8.20)  <0.001  
     PFHxS  1.30 (0.70-2.23)  1.72(1.10-
2.70)  
0.93(0.50-1.64)  <0.001  
     PFNA  0.74 (0.50-1.14)  0.80(0.55-
0.80)  
0.70(0.40-1.02)  <0.001  
Cancer, n (%)  407(9.1)  201(9.4)  206(8.8)  0.493  
  
The descriptive statistics were also analyzed by cancer diagnosis (Table 2).  Mean age 
was significantly higher in individuals with cancer compared to those who did not have cancer 
(about 18 years; p < .001).  Ethnicity, gender distribution was significantly different between the 
cancer diagnosis group and the no-cancer diagnosis grouping, while income was not.  Among 
those with cancer NHW ethnicity was predominant (65%), whereas only 15% NHB had cancer.  
Median serum PFAS was significantly higher in those with cancer compared with individuals 
without cancer (p < .05 for all).  
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Table 2 
Descriptive Characteristics of NHANES 2011-2016 Participants, by Cancer Diagnosis 
 Cancer No-cancer p-value* 
Age (years), mean ±SD 65.66 (13.06) 47.37(17.16) <.001 
Gender    .471 
     Male 201(49.4) 1947(47.6)  
     Female 206(50.6) 2143(52.4)  
Annual Household Income, n (%)   .793 
     Low  124(30.5) 1223(29.9)  
     Medium  128(31.4) 1240(30.3)  
     High 155(38.1) 1627(39.8)  
Ethnicity, n (%)   <.001 
     NHW 265(65.1) 1458(35.6)  
     NHB 61(15.0) 959(23.4)  
     Others 81(19.9) 1673(40.9)  
PFASs (ng/mL) Median, IQR    
     PFOA 2.17(1.59) 1.87(1.59) <.001 
     PFOS 7.80(8.27) 5.800(6.69) <.001 
     PFHxS 1.60(1.52) 1.30(1.50) <.001 
     PFNA 0.80(.71) 0.720(.62) 0.010 
 
Table 3 shows the unadjusted odds ratios of cancer with exposure to PFAS by gender.  
Among males, out of the four PFAS analyzed, only PFOS was associated with cancer diagnosis. 
Compared to the referent low PFOS group, males who had “high” serum PFOS demonstrated a 
115% significant elevated risk of cancer (odd ratio of 2.15, CI: 1.502, 3.078).  In contrast, among 
females except PFNA, all PFAS showed a dose dependent elevated risk of cancer.   
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Table 3 
Unadjusted Odds Ratio (95% Confidence Interval) of Cancer with Exposure to PFASs in 
NHANES 2011-2016 Participants, by Gender 
 Male Females 
 OR(95% CI) p-value* OR (95% CI) p-value* 
PFOA     
     Low Referent  Referent  
     Medium  1.105 (0.765, 1.595) 0.595 1.825 (1.222, 2.726) .003 
     High  1.339 (0.940, 1.908) 0.106 2.317 (1.563, 3.435) <.0001 
PFOS     
     Low Referent  Referent  
     Medium  1.144 (0.768, 1.702) .508 1.597 (1.071, 2.383) .022 
     High  2.150 (1.502, 3.078) <.0001 2.569 (1.764, 3.743) <.0001 
PFHxS     
      Low Referent  Referent  
      Medium  1.270 (0.881, 1.831) .200 2.192 (1.437, 3.344) <.0001 
      High  1.371 (0.956, 1.965) .086 3.350 (2.242, 5.006) <.0001 
PFNA     
      Low Referent  Referent  
      Medium  1.355 (0.960, 1.913) .084 1.110 (0.775, 1.589) .569 
      High  1.422 (0.951, 2.126) .086 1.384 (0.980, 1.955) .065 
 
 Age adjusted odds ratios and multivariable logistic regression (Tables 4 and 5) did not 
show any significant association between PFAS and cancer neither in males or females. 
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Table 4 
Age Adjusted Odds Ratio (95% Confidence Interval) of Cancer with Exposure to PFASs in 
NHANES 2011-2016 Participants, by Gender 
  Male   Females  
PFAS Unadjusted  MV adjusted  
  OR(95% CI)  p-value*  OR(95% CI)  p-value*  
PFOA          
Low  Referent    Referent    
Medium   1.016(0.689, 1.499)  .935  1.229(0.808, 1.868)  .335  
High   1.038(0.706, 1.527)  .849  1.092(0.715, 1.668)  .683  
          
PFOS          
Low  Referent    Referent    
Medium   0.804(0.519, 1.245)  .327  1.018(0.668, 1.552)  .933  
High   0.848(0.566, 1.270)  .424  1.039(0.683, 1.581)  .858  
          
PFHxS          
Low  Referent    Referent    
Medium   1.031(0.689, 1.542)  .883  1.462(0.942, 2.269)  .090  
High   0.952(0.641, 1.414)  .807  1.409(0.904, 2.195)  .130  
          
PFNA          
Low  Referent    Referent    
Medium   0.937(0.639, 1.373)  .738  0.789(0.541, 1.150)  .217  
High   0.874(0.563, 1.357)  .548  0.562(0.527, 1.101)  .148  
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Table 5 
Multivariable Adjusted Odds Ratio (95% Confidence Interval) of Cancer with Exposure to 
PFASs in NHANES 2011-2016 Participants, by Gender  
  Male Females 
PFAS Unadjusted MV adjusted 
  OR(95% CI)  p-value*  OR(95% CI)  p-value*  
PFOA          
Low  Referent    Referent    
Medium   0.843(0.552, 1.289)  .431  1.134(0.742, 1.733)  .561  
High   0.748(0.496, 1.127)  .165  1.004(0.652, 1.545)  .986  
PFOS          
Low  Referent    Referent    
Medium   0.797(0.506, 1.256)  .328  0.985(0.645, 1.505)  .945  
High   0.792(0.517, 1.214)  .285  1.103(0.720, 1.688)  .652  
PFHxS          
Low  Referent    Referent    
Medium   0.916(0.602, 1.396)  .684  1.431(0.920, 2.226)  .112  
High   0.806(0.531, 1.222)  .309  1.340(0.858, 2.090)  .198  
PFNA          
Low  Referent    Referent    
Medium   0.847(0.566, 1.267)  .419  0.799(0.546, 1.168)  .247  
High   0.950(0.597, 1.512)  .828  0.837(0.547, 1.221)  .356  
 
In secondary analysis, selected gender specific cancers were also analyzed including 
breast and prostate cancer.  The odds breast cancer in unadjusted analysis (Table 6) was 
significantly elevated in women who had high PFOS exposure as well in women with medium 
and high PFHxS exposure.  However, adjusted OR for breast cancer were not significantly 
elevated.  Unadjusted OR for prostate cancer in the high exposure category was significant for 
PFOS, PFHxS, and PFNA; however, the odds ratios were not significant in multivariable logistic 
regression (Table 7). 
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Table 6 
Unadjusted Odds Ratio (95% Confidence Interval) of Breast Cancer with Exposure to PFASs in 
NHANES 2011-2016 Female Participants  
Female Breast Cancer 
PFAS  Unadjusted MV adjusted 
 OR(95% CI) p-value* OR(95% CI) p-value* 
PFOA      
     Low  Referent  Referent  
     Medium   1.915(0.866,4.232) .108 1.149(0.509, 2.597) .738 
     High   2.166(0.985, 4.760) .054 0.833(0.362, 1.914) .666 
PFOS     
     Low  Referent  Referent  








PFHxS      
     Low  Referent  Referent  
     Medium   3.262(1.296, 8.213) .012 1.905(0.739, 4.910) .182 
 
     High   4.332(1.767, 10.620) .001 1.463(0.560, 3.823) .437 
 
PFNA      
     Low  Referent  Referent  
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Table 7 
Unadjusted Odds Ratio (95% Confidence Interval) of Prostate Cancer with Exposure to PFASs 
in NHANES 2011-2016 Male Participants  
  Male Prostate Cancer 
PFAS Unadjusted MV adjusted 
  OR(95% CI) p-value* OR(95% CI) p-value* 
PFOA      
     Low  Referent    
     Medium   1.045(0.549, 1.991) .893 0.894(0.453, 1.766) .747 
     High   1.563(0.865, 2.825) .139 1.098(0.587, 2.053) .771 
PFOS     
     Low  Referent  Referent  
     Medium   1.273(0.608, 2.667) .522 0.865(0.400, 1.870) .712 
     High   3.063(1.614, 5.813) .001 1.071(0.539, 2.126) .845 
PFHxS      
     Low Referent  Referent  
     Medium 1.550(0.798, 3.013) .198 1.185(0.592, 2.373) .632 
     High 2.062(1.096, 3.879) .025 1.296(0.666, 2.521) .445 
PFNA      
     Low  Referent  Referent  
     Medium 1.616(0.828, 3.154) .159 0.960(0.475, 1.941) .910 
     High 3.276(1.666, 6.442) .001 1.840(0.898, 3.769) .096 
 
Discussion 
In this this analysis of selected NHANES participants, the unadjusted models showed a 
significant association between PFHxS and cancer in males and a significant relationship of 
PFOA, PFOS, and PFHxS with cancer in females.  However, the age adjusted and multivariate 
models did not show a statistically significant relationship.  In addition, selected cancers for 
males (prostate cancer) and females (breast cancer) also showed a significant unadjusted 
association with PFAS levels, this was not the case with multivariate analyses.  
Previous animal studies have a shown a dose related association of PFAS compounds to 
testicular cancer, liver and pancreatic adenomas, mammary tissue adenomas, and prostate cancer.  
There is some evidence of PFAS and linkage with risk of cancer in human studies (Vieira, et al., 
2012).  In addition, there have been reported marked intergender differences in the elimination of 
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PFOA in rats and substantial differences in the half-life of PFOA in rats, monkeys, and humans; 
the potential to estimate risks to humans from animal doses is uncertain (Centers for Disease 
Control & Prevention [CDC], 2009).  The CDC (2009) also commented that PFOS levels appear 
to be two to threefold higher in the US than other comparable countries such as Brazil, Poland, 
Belgium, and Japan. 
Carcinogenicity of PFASs remains unclear.  Of the 5000 or so PFASs currently used, 
only PFOA has been categorized as “2B possible human carcinogen” by the World Health 
Organization’s International Agency for Research on Cancer (IARC) 
(https://monographs.iarc.fr/wp-content/uploads/2018/06/mono110-01.pdf).  This categorization 
is based on “limited” evidence for testicular and renal cancer from studies in human and 
experimental animals.  The US Environmental Protection Agency has also classified PFOA’s 
carcinogenic potential as “likely to be carcinogenic” in 2016 (Donohue, Duke, & Wambaugh, 
2016).  
Mechanistic data for PFOA shows that it is not metabolized in humans and is fully 
reabsorbed after filtration in the kidneys leading to much longer retention in the body when 
compared with all other tested animals.  Therefore, the body burden of PFOA experienced by 
humans is much greater than in animal models.  
The proposed mechanism of carcinogenicity for PFOA is thought to be due to induction 
of oxidative stress, hepatotoxity, and liver injury.  Other mechanisms that could play a role in 
carcinogenesis include tumor induction, endocrine disruption, developmental toxicity, and, 
immune-toxicity.   
In laboratory animals the liver is a well-known target for PFOA toxicity.  The molecular 
mechanisms for PFOA-induced hepatotoxicity and carcinogenicity in the liver include PPARα 
PFASs AND CANCER RISK 18 
activation, involvement of other molecular pathways such as estrogen receptor and cytotoxicity.  
Other possible pathways are hypothesized to be via modulation of inflammatory pathways.  
Studies in human cells, rodents, and fish, have documented perturbation of molecular pathways 
involving reproductive hormones and hormone receptors, such as activation of estrogen receptor.  
A recent nested case-control study conducted in French postmenopausal women (non-
occupational exposure) suggests a dose-response relationship between PFOS serum 
concentrations and the risk of hormone receptor-positive breast cancer (Mancini et al., 2019). 
Our study did show positive cancer relationships between several PFAS, and these 
appeared to be more robust in the female population.  The median respective PFAS levels 
between males and females were significantly different (males greater than females), suggesting 
that there may be a gender association in humans, possibly due to occupational exposure, gender 
differences in physiologic elimination, or diet related.  Given that the females, despite having 
lower PFAS levels in general, had more frequent positive associations with cancer might suggest 
that they are more sensitive to PFAS.  This would be a possible area of additional research.   
Strengths 
The study had several strengths.  Data from NHAHES represents a state of the art 
biomonitoring of US population.  It includes detailed sociodemographic information, dietary and 
health related questions that are helpful in epidemiologic studies in general population to monitor 
common environmental exposures and health outcomes.  Their methods of data collection have 
been repeatedly tested and are a subject to continuous process improvement.  In this study, race 
and socioeconomic status were included in the model.  To our current knowledge, this is the first 
analysis to explore link between PFAS isomers and cancer in NHANES data.  
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Weaknesses 
The study did have several weaknesses.  A cross-sectional study does not allow 
assessment of causations between PFAS and cancer.  In addition, the multivariate analysis could 
have included BMI (given the potential endocrine disruptive properties of PFAS) and smoking, 
(a significant carcinogen) to adjust for other potential cancer risk factors.  Multiple specific 
cancer types have been associated with both animal and human models with PFAS exposure; 
however, those specific cancer types in this analysis dis not have a robust sample size.  Given the 
unadjusted result with the specific cancer types, especially in the female analysis, this would 
likely be an area for further research. 
Conclusion 
 According to the results of our study, PFAS levels were did not show a statistically 
significant association with cancer in the multivariable regression model.  Although the study did 
utilize an extended dataset over multiple survey cycles, it would likely benefit from a larger 
number of participants.    
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Appendix A: Human Subjects Regulations Decision Chart 
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Evidence-based Approaches to Public Health 
 
1. Select quantitative and qualitative data collection methods appropriate for a given public health context 
2. Analyze quantitative and qualitative data using biostatistics, informatics, computer-based programming 
and software, as appropriate 




1. Demonstrate application of an advanced quantitative or qualitative research methodology 
2. Demonstrate the ability to contextualize and integrate knowledge of specific population health issues. 
 
 
